See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Epicrispr banks $68M to test epigenetic editing on rare muscle disease

Summary by biopharmadive.com
The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

4 Articles

All
Left
Center
1
Right
biopharmadive.combiopharmadive.com
Center

Epicrispr banks $68M to test epigenetic editing on rare muscle disease

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

Read Full Article
GEN - Genetic Engineering and Biotechnology News…GEN - Genetic Engineering and Biotechnology News…

Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

Read Full Article
FinSMEsFinSMEs

Epicrispr Biotechnologies Raises $68M in Series B Funding

Epicrispr Biotechnologies, a South San Francisco, CA-based biotechnology company focused on developing curative therapies, raised $68m in the first close of its Series B financing. The round was led by Ally Bridge Group, with participation from SOLVE FSHD, the venture philanthropy organization founded by Chip Wilson, founder of Lululemon Athletica and FSHD patient, along with […] The post Epicrispr Biotechnologies Raises $68M in Series B Funding…

Read Full Article
Endpoints NewsEndpoints News

Epicrispr raises $68M, will start clinical trial of epigenetic editing for FSHD

Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive muscle disease called facioscapulohumeral muscular dystrophy, or FSHD. She was a pharmaceutical executive who had ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

Similar News Topics

Startups

Startups

CRISPR

CRISPR

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal